Comparison of labetalol and propranolol in hypertension

British Journal of Clinical Pharmacology
D P NichollsA G Butler

Abstract

1 Labetalol has been compared with propranolol in a double-blind, double-dummy study of 24 patients with mild or moderate essential hypertension. 2 Two patients were unable to tolerate propranolol and five labetalol, because of symptom side effects; this difference was not significant (P greater than 0.1). 3 On a self-administered questionnaire, labetalol was associated with a greater number of side effects per patient than propranolol, but no individual side effect was significantly more common with either drug. 4 There was no difference in the number of spontaneously reported side effects between the two drugs. 5 Both drugs impaired pulmonary function, but propranolol caused a greater reduction than labetalol after 8 weeks of treatment. 6 We conclude that labetalol and propranolol are similarly effective and acceptable to the patient.

References

Jan 1, 1977·British Heart Journal·D A RichardsE J Knight
Aug 1, 1977·British Heart Journal·D W Barritt, A J Marshall
Aug 6, 1977·Lancet·A S HuaP Kincaid-Smith
Feb 25, 1978·Lancet·W J LouisF J Vajda
Apr 12, 1975·British Medical Journal·C SkinnerK N Palmer
Apr 1, 1978·British Medical Journal·R W Gange, E W Jones
Dec 18, 1978·European Journal of Clinical Pharmacology·G L SandersM D Rawlins
May 1, 1976·British Medical Journal·M H Frick, P Pörsti
May 6, 1972·Lancet·L J Beilin, B E Juel-Jensen
Aug 1, 1974·Journal of Chronic Diseases·C J BulpittS Carne
Sep 1, 1973·British Medical Journal·C J Bulpitt, C T Dollery
Jun 1, 1974·British Heart Journal·P A MajidS H Taylor
Sep 19, 1964·British Medical Journal·B N PRICHARD, P M GILLAM

❮ Previous
Next ❯

Citations

Jan 1, 1984·European Journal of Clinical Pharmacology·M M Kubik, J H Coote
Jan 1, 1985·European Journal of Clinical Pharmacology·E D CookeA T Smith
Jan 1, 1983·Pharmacology & Therapeutics·A J Scriven, P J Lewis
Jan 27, 2018·The Cochrane Database of Systematic Reviews·Elizabeth N AllenKaren Barnes
Jan 1, 1982·Acta Medica Scandinavica. Supplementum·G Nyberg, G Berglund
Jan 1, 1982·Acta Medica Scandinavica. Supplementum·R A WalstadO G Nilsen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.